Aurobindo Pharma Subsidiary Apitoria Completes A1 Biochem Acquisition to Strengthen CRDMO Business
Aurobindo Pharma Ltd 路 Others (Uncategorized) 路 03 Oct 2026, 12:05 am
Aurobindo Pharma Subsidiary Apitoria Completes A1 Biochem Acquisition to Strengthen CRDMO Business Aurobindo Pharma announced that its wholly owned subsidiary, Apitoria Pharma, completed the acquisition of A1 Biochem Group's contract research services business on 2nd Oct'26. Apitoria now holds an 80% stake in A1 Biochem Labs (India), while former promoter Dr. Rajendra Gadikota retains 20%. Concurrently, A1 Labs India acquired 100% of US-based A1 Biochem Labs LLC. The transaction provides Apitoria access to an established CRO platform with 50+ clients and 800+ completed projects, advancing its transition into an integrated CRDMO platform across India and the US.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
